No Data
Shanghai Shen Lian Biomedical Corporation (688098.SH): A total of 0.832% of shares have been repurchased.
On March 4th, Gelonghui reported that Shanghai Shen Lian Biomedical Corporation (688098.SH) announced that as of February 28, 2025, the company had repurchased a total of 3,416,473 shares through a dedicated repurchase account via centralized bidding, accounting for 0.8320% of the total share capital of the company. The highest price for the repurchase was 6.29 yuan per share, the lowest price was 5.47 yuan per share, and the total amount paid was 19,995,169.13 yuan (excluding transaction fees such as stamp duty and trading commissions).
Shen Lian Biomedical Obtains Certification, Production License for New Vaccine Lines
Shenlian Biotech: 2024 Annual Results Express Announcement
2024 Annual Results Express Announcement
Shanghai Shen Lian Biomedical Corporation (688098.SH): Obtained the "Veterinary Drug GMP Certificate" and "Veterinary Drug Manufacturing License."
On February 27, Gelonghui reported that Shanghai Shen Lian Biomedical Corporation (688098.SH) announced that its Lanzhou branch has recently passed the veterinary drug GMP acceptance and obtained the "Veterinary Drug GMP Certificate" and "Veterinary Drug Production License" issued by the Gansu Provincial Animal Husbandry and Veterinary Bureau. New production lines for cell suspension culture virus inactivated vaccines (including cell suspension culture virus subunit vaccines), cell suspension culture subunit vaccines, and bacterial inactivated vaccines have all passed the veterinary drug GMP acceptance.
Shanghai Shen Lian Biomedical Corporation (688098.SH): Today, Cheng made an additional investment of 60 million yuan in Shizhiyuan.
On February 5, Glonghui reported that Shanghai Shen Lian Biomedical Corporation (688098.SH) held its second meeting of the fourth Board of Directors and the second meeting of the fourth Supervisory Board on February 5, 2025. The meetings reviewed and approved the proposal regarding the external investment and related transactions of its wholly-owned subsidiary. It was agreed that the company would increase the capital or provide loans to its wholly-owned subsidiary, Ben Tian Cheng, which would invest 60 million yuan to increase the capital of Shi Zhi Yuan. After the completed capital increase, the company would indirectly hold 20.48% of Shi Zhi Yuan’s equity through Ben Tian Cheng, making Shi Zhi Yuan an associated company of the company. Shi Zhi Yuan plans to engage in synthetic peptides and peptide drugs in the future.
Pinning Down Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) P/S Is Difficult Right Now